IMUNON Highlights Phase 3 OVATION 3 Trial at R&D Day
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
